Skip to main navigation Skip to search Skip to main content

Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer

  • Graham Caine
  • , AL Harris
  • , K Christodoulos
  • , Gregory Lip
  • , Andrew Blann

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The effects of combination anti-angiogenesis therapy (marimastat, captopril and fragmin) on plasma levels of coagulation initiator tissue factor (TF), platelet marker soluble P-selectin and angiogenic vascular endothelial growth factor (VEGF) were tested in 25 patients with advanced cancer. They had higher soluble P-selectin (P
Original languageEnglish
Pages (from-to)163-7
Number of pages5
JournalCancer Letters
Volume219
Issue number2
DOIs
Publication statusPublished - 10 Mar 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer'. Together they form a unique fingerprint.

Cite this